David Groshar
Papers
1
Total Citations
37
H-Index
1
About
David Groshar is a leading figure in nuclear medicine and molecular imaging, with a primary focus on theranostics for prostate cancer. His most impactful contributions center on the development and clinical translation of radionuclide therapies, particularly using prostate-specific membrane antigen (PSMA) ligands. In a landmark single-arm Phase 1 trial, Groshar demonstrated the feasibility and safety of neoadjuvant 177Lu-PSMA-I&T treatment in high-risk prostate cancer patients prior to radical prostatectomy, a study that has garnered 37 citations since 2022 and opened new avenues for combined radio-surgical approaches. His work bridges the gap between diagnostic imaging and targeted radiotherapy, establishing protocols that personalize treatment for aggressive disease. With a career spanning decades, Groshar has been instrumental in advancing theranostic paradigms, influencing both clinical guidelines and ongoing trials. His research continues to shape how clinicians integrate molecularly targeted radiation into multidisciplinary cancer care, offering patients with high-risk prostate cancer a potential path to improved outcomes.
Research Focus
Key Achievements
Top Papers
- 1